Why the study?
Extracellular vesicles show potential as cell-free therapy for myocardial infarction, but low heart-targeting efficiency and short plasma half-life hamper their clinical translation.
Answers are grounded in this paper and cite their sources.
This review highlights current strategies and challenges in improving the heart-targeting efficiency of extracellular vesicle therapies for myocardial infarction.
Cardiovascular diseases rank the highest incidence and mortality worldwide. As the most common type of cardiovascular disease, myocardial infarction causes high morbidity and mortality. Recent studies have revealed that extracellular vesicles, including exosomes, show great potential as a promising cell-free therapy for the treatment of myocardial infarction. However, low heart-targeting efficiency and short plasma half-life have hampered the clinical translation of extracellular vesicle therapy. Currently, four major types of strategies aiming at enhancing target efficiency have been developed, including modifying EV surface, suppressing non-target absorption, increasing the uptake efficiency of target cells, and utilizing a hydrogel patch. This presented review summarizes the current research aimed at EV heart targeting and discusses the challenges and opportunities in EV therapy, which will be beneficial for the development of effective heart-targeting strategies.
No takes yet. Share an insight, caveat, or question.
Yin et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: